A new therapeutic approach for bone metastasis in colorectal cancer: intratumoral melittin

• Autor(a) principal: Rocha, Mackson Martins
• Data de Publicação: 2022
• Outros Autores: Dariva, Isabela, Zornoff, Gabriela Comelli, De Laurentis, Giovanna Sanches, Mendes, Giulia Carli, Santana, Maycon Giovani, Miguel, Guilherme Chohfi de, Ferreira, Rui Seabra [UNESP], Sciani, Juliana Mozer, Priolli, Denise Goncalves
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.1590/1678-9199-JVATITD-2021-0067; http://hdl.handle.net/11449/218845
• topic: Bone metastasis; Melittin; Intratumoral injection; Colorectal neoplasms; Bee venom

Background: Melittin has shown antiproliferative effects on tumor cells. Therefore, it comprises a valuable compound for studies on cancer treatment. To the best of our knowledge, no studies have reported melittin effects on bone metastasis. Herein, we propose an approach based on intrametastatic melittin injection to treat bone metastases in colorectal cancer. Methods: Following the characterization of melittin and antiproliferative tests in vitro, a single dose was injected through intrametastatic route into the mouse bone metastasis model. Following treatment, metastasis growth was evaluated. Results: A single dose of melittin was able to inhibit metastasis growth. Histological analysis showed necrosis and inflammatory processes in melittin-treated metastasis. Except by mild weight loss, no other systemic effects were observed. Conclusion: Our data suggest that melittin might be a promising agent for the future development of treatment strategies aiming to reduce the metastasis skeletal-related impact in colorectal cancer patients with bone metastasis.